中国誓言控制滥用抗生素药物

2016-09-06 佚名 参考消息网

外媒称,中国作为世界人用和兽用抗生素的最大消费国,誓言要加强新型抗菌药物的研发并控制现有药物的过度使用,以应对不断加剧的细菌耐药性问题。据美国《科学》周刊网站8月31日报道,中国中央政府8月26日发布一项国家行动计划,称将调动包括卫生、食品药品和农业等14个部委的力量。政府的目标是,到2020年研发几种新型抗菌药物,凭处方才能销售抗菌药物,加强对人用和兽用抗菌药物使用的监管,加强对医务人员和消费者

外媒称,中国作为世界人用和兽用抗生素的最大消费国,誓言要加强新型抗菌药物的研发并控制现有药物的过度使用,以应对不断加剧的细菌耐药性问题。

据美国《科学》周刊网站8月31日报道,中国中央政府8月26日发布一项国家行动计划,称将调动包括卫生、食品药品和农业等14个部委的力量。政府的目标是,到2020年研发几种新型抗菌药物,凭处方才能销售抗菌药物,加强对人用和兽用抗菌药物使用的监管,加强对医务人员和消费者抗菌药物合理应用的培训。该计划没有详述资金和新药研发的情况。

据英国韦尔科姆基金会5月的一份报告,到2050年中国细菌耐药性问题每年有可能造成100万例早夭,使这个国家付出20万亿美元(约合133.6万亿元人民币)的代价。目前在中国,人用和兽用抗生素泛滥,不用处方就能得到。中国每年的抗菌药物消耗量占世界的一半。世卫组织(WHO)驻华代表施贺德说:“细菌耐药性是人类行为造成的问题——主要通过医疗保健和畜牧业不合理应用抗菌药物造成。这就是为什么这项国家行动计划如此重要——它提出了应对这个问题的综合方案。”在记者会上,WHO列举了几个在中国助长抗生素耐药性的关键问题。医师和兽医缺少快速诊断方法,结果在没必要和无用的情况下也会依赖抗生素。不凭处方就能买到抗菌药物的情况大大增加了药物的过度使用,同时医院也依靠卖药获利。消费者和农民也要求快速方便地获取抗菌药物,并过于频繁地使用,造成抗菌药物的药效下降。

报道称,在中国抗菌药物过度滥用的情况已经被指造成潜在的灾难性后果。2015年11月,华南农业大学的研究人员在英国《柳叶刀·传染病》杂志上发表一篇论文,报告发现对粘菌素出现耐药性,而粘菌素通常是终极抗生素。先前之所以没有出现对这种抗生素的耐药性,一部分原因是一般只有在其他药物无效的情况下才会使用它。研究人员发现,在中国,带来耐药性的基因已经在细菌中传播。粘菌素被广泛用作牲畜的预防药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701528, encodeId=a9bc1e01528d4, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Jan 06 03:55:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112232, encodeId=8139112232f1, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112233, encodeId=464d11223391, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112230, encodeId=e3cf11223052, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:46:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112229, encodeId=d30e112229c8, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:45:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2017-01-06 zchen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701528, encodeId=a9bc1e01528d4, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Jan 06 03:55:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112232, encodeId=8139112232f1, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112233, encodeId=464d11223391, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112230, encodeId=e3cf11223052, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:46:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112229, encodeId=d30e112229c8, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:45:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1701528, encodeId=a9bc1e01528d4, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Jan 06 03:55:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112232, encodeId=8139112232f1, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112233, encodeId=464d11223391, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112230, encodeId=e3cf11223052, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:46:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112229, encodeId=d30e112229c8, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:45:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1701528, encodeId=a9bc1e01528d4, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Jan 06 03:55:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112232, encodeId=8139112232f1, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112233, encodeId=464d11223391, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112230, encodeId=e3cf11223052, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:46:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112229, encodeId=d30e112229c8, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:45:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1701528, encodeId=a9bc1e01528d4, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Jan 06 03:55:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112232, encodeId=8139112232f1, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112233, encodeId=464d11223391, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:48:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112230, encodeId=e3cf11223052, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:46:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112229, encodeId=d30e112229c8, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:45:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续学习

    0

相关资讯

Structure:关键蛋白或助力新型抗生素开发之路

图片来源:www.phys.org近日,一项刊登在国际杂志Structure上的研究报告中,来自俄勒冈州立大学的研究人员通过研究首次对过氧化物氧化还原酶(peroxiredoxin,一种抗氧化蛋白)进行了原子水平的成像以及详细解析,研究者指出,解析该蛋白质的特性或有望开发出新一代抗生素。 文章中,研究者利用X射线晶体学技术研究了过氧化物氧化还原酶的本质特性和行为,机体中所有的细胞都需要过氧化物氧

一岁大的婴儿真的需要用抗生素治疗嘛?

三分之二的儿童在其一岁时就接受过抗生素进行疾病治疗,如今抗生素的使用率在澳大利亚越来越高,然而抗生素的不断使用也会影响机体抗生素耐药性的产生,如今抗生素的使用已经处于风险危机水平了,这就意味着未来很多感染性疾病也变得难以治疗。因此如果你有一个10个月大的孩子的话,那么作为父母的你或许就应当知道,或者你应当向家庭医生进行咨询抗生素使用的益处和风险。很多医生认为,对于婴儿的疾病父母仅仅或许需要

几首抗生素使用口诀 !

临床中,抗生素种类繁多,死记硬背是件头疼的事情。但是,要熟悉各种抗生素的抗菌谱对于指导临床用药有很大的帮助,今天,我们就来学习一下,常见抗生素及其抗菌谱。 1.头孢类抗生素分类:一拉定唑林氨苄二呋孟替克丙烯三肟他啶哌曲松四代吡肟骑匹马五代洛林托罗普 内容解释:一代四种:头孢拉定、头孢唑林、头孢氨苄、头孢羟氨苄;二代五种:头孢呋辛、头孢孟多、头孢替啶、头孢克洛、头孢丙烯;三代六种

强行科普:滥用抗生素,危害到底有多大?!

近日,央视曝光,同样是麦当劳,我们吃的却和美国不一样!据央视报道英国一家慈善机构呼吁消费者向麦当劳首席执行官史蒂夫·伊斯特布鲁克发电子邮件,要求麦当劳在全球范围内,停止供应使用过抗生素的肉类和乳制品,以防止出现更多的超级细菌。这家机构希望通过消费者电邮引起麦当劳重视,让麦当劳在全球范围内供应的鸡肉、牛肉、猪肉和乳制品中,都不再出现滥用抗生素的问题,而不是仅在美国的麦当劳停用含抗生素的产品。麦当劳宣

克林霉素滥用严重,10大不良反应须警惕!

克林霉素,抗生素类药物。为林可霉素的衍生物,自1970年在我国上市,已有40多年的使用历史,一般用于革兰氏阳性菌引起的感染性疾病,克林霉素抗菌谱广,抗菌效力强,不用做皮试,在临床上获得了越来越广泛的应用。克林霉素在应用中最常见的不良反应:过敏反应、注射局部刺激和肝功能异常,最严重的是伪膜性肠炎。克林霉素的不良反应日益受到人们关注。如果能够合理用药,密切观察,及时处理、抢救,这些不良反应是可以预测和

Am J Med:抗生素也能导致这么高的低钠血症发生率?

复方新诺明(TMP-SMX)为磺胺类抗菌药,是磺胺甲恶唑(SMZ)与甲氧苄啶(TMP)的复方制剂,对非产酶金黄色葡萄球菌、化脓性链球菌、肺炎链球菌、大肠埃希菌、克雷伯菌属、沙门菌属、变形杆菌属、摩根菌属、志贺菌属等肠杆菌科细菌、淋球菌、脑膜炎奈瑟菌、流感嗜血杆菌均具有良好抗菌作用,尤其对大肠埃希菌、流感嗜血杆菌、金黄色葡萄球菌的抗菌作用较SMZ单药明显增强。在临床上常使用高剂量的TMP-SMX治疗